A smorgasbord of challenges face radiology but few present a greater threat than the “invisible radiologist,” said Dr. Gary Glazer, chairman of the Stanford University radiology department, who kicked off the 11th International Symposium on Multidetector-Row CT.
A smorgasbord of challenges face radiology but few present a greater threat than the “invisible radiologist,” said Dr. Gary Glazer, chairman of the Stanford University radiology department, who kicked off the 11th International Symposium on Multidetector-Row CT.
Glazer flashed a four-year-old New York Times story on the screen, an anecdote of a woman who waited weeks to learn the results of a CT scan. The suspicious lesion was noncancerous, but the experience was a nightmare. The story crystallized concerns by Glazer about the invisibility of the radiologist.
“It is quite clear, in a high percentage, as high as 90%, that the patient never speaks with the physician interpreting the scan,” Glazer said. “There has been a huge amount of work undertaken over the last decade at improving efficiency of workflow and developing ideal workstations – but these sorts of questions have all related to the life of the radiologist. The patient has been nowhere in this consideration.”
This must change in the years to come, he said. “If healthcare is to improve, the interaction of radiologist and patients must be optimized,” Glazer said.
Among the other challenges and, by extension, opportunities for radiology is for CT to push the boundaries of biology not so much for diagnostic as therapeutic purposes. Glazer said CT has a role to play in personalized medicine, particularly in helping physicians tailor drug therapy to improve outcomes and reduce costs by focusing on those that are effective. This will be done by moving backwards from the image to the molecular underpinnings of disease by correlating what is seen in radiology to genomics, he said.
What is the Best Use of AI in CT Lung Cancer Screening?
April 18th 2025In comparison to radiologist assessment, the use of AI to pre-screen patients with low-dose CT lung cancer screening provided a 12 percent reduction in mean interpretation time with a slight increase in specificity and a slight decrease in the recall rate, according to new research.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
Can CT-Based AI Radiomics Enhance Prediction of Recurrence-Free Survival for Non-Metastatic ccRCC?
April 14th 2025In comparison to a model based on clinicopathological risk factors, a CT radiomics-based machine learning model offered greater than a 10 percent higher AUC for predicting five-year recurrence-free survival in patients with non-metastatic clear cell renal cell carcinoma (ccRCC).
Could Lymph Node Distribution Patterns on CT Improve Staging for Colon Cancer?
April 11th 2025For patients with microsatellite instability-high colon cancer, distribution-based clinical lymph node staging (dCN) with computed tomography (CT) offered nearly double the accuracy rate of clinical lymph node staging in a recent study.